Streptococcus pneumoniae News and Research

RSS

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.

S. pneumoniae interacts with other nasopharyngeal bacteria

Streptococcus pneumoniae bacteria are able to detect and respond to other bacterial species in the same host niche, researchers report in Open Biology.

12 May 2014

Inflammatory pneumococcal response differs by age

The composition of inflammatory lung infiltrate in people with pneumonia caused by Streptococcus pneumoniae differs by age, an in-situ study reveals.

6 May 2014

Pediatric viral respiratory tract infection often complicated by bacterial sinusitis

Nearly 1 in 10 cases of viral upper respiratory tract infections in infants and young children is complicated by acute bacterial sinusitis, often in conjunction with acute otitis media, a longitudinal cohort study has found.

22 Apr 2014

S. pneumoniae serotypes differ between primary and post-viral disease

Certain capsular serotypes of Streptococcus pneumoniae are particularly likely to cause disease in people who have recently experienced a respiratory viral infection, study findings indicate.

14 Apr 2014

S. pneumoniae is commonest cause of paediatric CAP

Streptococcus pneumoniae is the predominant cause of community-acquired pneumonia among children in Belgium, with non-vaccine serotypes accounting for the majority of cases, a Belgian study shows.

31 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

Low dose injections of artificial properdin provides protection against septic diseases in mice

Breakthrough MRC-funded study from University of Leicester shows low dose injections of artificial properdin provides substantial protection against septic diseases in mice

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Low dose injections of artificial properdin provide protection against septic diseases

Researchers at the University of Leicester have produced an artificial version of a naturally occurring protein, properdin, which has been found to successfully combat bacterial pneumonia and meningitis when tested in mice.

25 Mar 2014

CSP analogues may attenuate S. pneumoniae virulence, resistance

The spread of virulent, antibiotic-resistant strains of Streptococcus pneumoniae may be controllable through the use of competence-stimulating peptide analogues, US researchers believe.

24 Mar 2014

Study examines events that lead to sepsis by Streptococcus pneumoniae

An international team of academics, including Professor Marco Oggioni from the University of Leicester's Department of Genetics, has studied how localised infections can turn into the dangerous systematic disease sepsis - and has identified for the first time through genetic evidence that a single bacteria could be the cause.

24 Mar 2014

S. pneumoniae thrives in human saliva

Streptococcus pneumoniae is able to survive and thrive in human saliva, Dutch researchers have shown.

17 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

Hypervirulent S. pneumoniae mutants discovered

Swedish researchers studying Streptococcus pneumoniae have discovered “hypervirulent” mutant forms of the bacteria that are selected for because they are more resistant to clearance by macrophages.

3 Mar 2014

S. pneumoniae highly prevalent in urban Indonesians, especially children

Streptococcus pneumoniae is present in the nasopharyngeal mucosa in nearly half of children under the age of 5 years and one in 10 adults living in Java Island, Indonesia, a survey has found.

25 Feb 2014

Invasive pneumococcal disease in Taiwan on the wane, but threats remain

The incidence of invasive pneumococcal disease in Taiwan has decreased significantly in recent years, study findings indicate.

17 Feb 2014

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise.

11 Feb 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014